Delivery technologies are required for realizing the clinical potential of molecular medicines. This work presents an alternative technology to preformulated delivery systems by harnessing the natural transport properties of serum albumin using endogenous binding of gapmer antisense oligonucleotides (ASOs)/albumin constructs. We show by an electrophoretic mobility assay that fatty acid-modified gapmer and human serum albumin (HSA) can self-assemble into constructs that offer favorable pharmacokinetics. The interaction was dependent on fatty acid type (either palmitic or myristic acid), number, and position within the gapmer ASO sequence, as well as phosphorothioate (PS) backbone modifications. Binding correlated with increased blood circulation in mice (t 1/2 increased from 23 to 49 min for phosphodiester [PO] gapmer ASOs and from 28 to 66 min for PS gapmer ASOs with 2Â palmitic acid modification). Furthermore, a shift toward a broader biodistribution was detected for PS compared with PO gapmer ASOs. Inclusion of 2Â palmitoyl to the ASOs shifted the biodistribution to resemble that of natural albumin. This work, therefore, presents a novel strategy based on the proposed endogenous assembly of gapmer ASOs/ albumin constructs for increased circulatory half-life and modulation of the biodistribution of gapmer ASOs that offers tunable pharmacokinetics based on the gapmer modification design.
INTRODUCTION
Gene silencing by antisense oligonucleotides (ASOs) offers great potential as a therapeutic strategy. Gapmer ASOs are short singlestranded ASOs containing a central DNA sequence commonly flanked by a locked nucleic acid (LNA) sequence that interrupt mRNA expression by induction of RNase H activation, and exhibit cellular entry without the necessity of a transfection agent by a process termed gymnosis. [1] [2] [3] Stability and blood half-life extension technologies, however, are needed because of oligonucleotides susceptibility to serum nuclease degradation and rapid limited distribution into organs like the liver and kidney, resulting in a short blood circulatory half-life of $2-10 min. 4 Great efforts have been made to improve the plasma stability of ASOs, with a wide range of different chemical sugar modifications such as 2 0 -O-methyl (2 0 O-Me), 2 0 -O-methoxyethyl (2 0 MOE), and constrained ethyl (CEt; LNA containing a methyl substituent), 5 and backbone modifications from a phosphodiester (PO) to phosphorothioate (PS) design used. 6 The low molecular weight of ASOs, however, still results in rapid elimination from the blood that limits the potential to accumulate at target tissue sites.
A vast array of viral and non-viral vectors has been developed to improve the effectiveness of nucleic acid therapeutics; however, many vectors are based on complex designs, with cost and safety considerations that reduce the likelihood of clinical applications. 7 Harnessing the natural transport properties of endogenous serum albumin using nucleotide modifications that maximize binding offers a simple alternative without the necessity for elaborate preformulated delivery systems. Human serum albumin (HSA) is a transport protein for endogenous ligands such as fatty acids that has a long blood circulatory half-life of $19 days, predominantly because of engagement with the cellular recycling neonatal Fc receptor (FcRn). 8, 9 Its multiple ligand binding sites have been exploited in the design of albumin-binding drugs such as the insulin analog detemir and glucagon-like type-1 (GLP-1) agonist liraglutide modified with 14-carbon fatty acid 10 and palmitic acid, 11 respectively.
Previous work has implicated the involvement of HSA in the pharmacokinetics of PS ASOs because of non-specific interactions [12] [13] [14] suggested for the serum stability and increased half-life by rescue from renal clearance of the PS ASOs, compared with their PO counterparts. 13 A recent study suggested strong binding between PS ASOs and albumin; 15 however, the binding affinity of PS ASOs with albumin has previously been reported to be low (370-480 mM).
12 Thus, fatty-acid-modified gapmer ASOs may offer a greater likelihood to form an endogenous assembled construct with HSA for altering the pharmacokinetics of the ASO. This work introduces a delivery technology platform based on endogenous self-assembly of gapmer ASOs and HSA for tuning pharmacokinetics.
RESULTS
The chemical structure of the N2 0 -functionalized amino-LNA monomers presented in Table 1 show the fatty acid and backbone modification sites. The gapmer ASOs modified with either one or two palmitic or myristic acid residues at different locations within the ASO sequence were performed utilizing 2 0 -amino-LNA nucleosides as the modification site ( Figure 1 ). The interaction with recombinant HSA (rHSA) of a range of different fatty acid-modified gapmer ASO designs was investigated using an electrophoretic mobility shift assay (Figure 2 ). It was found that the number, position, and fatty acid modification influenced the binding affinity to albumin based on a modification screen of the gapmer ASOs. Increased binding affinity was observed with increased number of fatty acid modifications. Introduction of PS backbone linkages increased the binding affinity of fatty acid-modified ASOs to albumin; however, the increase was much less significant compared with that of fatty acid modifications.
Gapmer ASOs with 0Â and 2Â 3 0 palmitoyl modifications (referred to as 0Â Pal and 2Â Pal, respectively), with either PO or PS backbone linkages, were then used to investigate correlation between the binding data and blood circulatory half-life and biodistribution in mice. Addition of a Cy5.5 fluorescent tag to the 5 0 end of the gapmer ASOs was shown not to affect the binding affinity to albumin for the 0Â Pal and 2Â Pal ASOs with either PO or PS backbone linkages. For blood circulatory half-life and biodistribution studies, Cy5.5 fluorescent-labeled 0Â Pal and 2Â Pal gapmer ASOs were tracked using live fluorescent bioimaging. Gapmer ASOs (3.5 mg/kg in a total volume of 200 mL of either the 0Â Pal gapmer ASOs and equivalent moles of 2Â Pal PO, 0Â Pal PS, or 2Â Pal PS gapmer ASOs) were administered by a single bolus tail-vein intravenous injection into 8-to 9-week-old healthy female C57BL/6 mice (n = 5). Blood was collected from the tongue after 1 min by sublingual vein puncture, and by tail-nicking after 30 min, 2 hr, 4 hr, and 24 hr. Plasma was isolated and the fluorescence determined by an In Vivo Imaging Service (IVIS) scanner. Quantification of plasma fluorescence revealed a more than 2-fold increase in blood circulatory half-life for the palmitoylated PO gapmer ASOs, an 8-fold increase in signal from the liver and a 4-fold decrease in the signal in the kidney were observed compared with non-palmitoylated PO. The palmitoylated PS gapmer ASOs, however, showed a 2-fold decrease in the signal from the kidney but a 2-to 8-fold increase in signal for the rest of the organs compared with non-palmitoylated PO gapmer ASOs. The biodistribution of the palmitoylated ASOs/albumin assemblies shifted to a biodistribution resembling that of albumin, 16 supporting endogenous ASO/HSA binding and involvement of albumin in the transport of palmitoylated gapmer ASOs. 
DISCUSSION
Site-specific delivery is a challenge to the clinical translation of nucleic-acid-based therapeutics. In this work we modulate binding to HSA to control gapmer ASOs pharmacokinetics. Utilization of an endogenous assembly process allows harnessing the natural transport properties of albumin 17, 18 without the necessity for elaborate preformulated designs and associated adverse effects with many delivery systems.
Previous work has shown a rapid exponential clearance from peak plasma concentrations of ASOs following intravenous injection, with a serum half-life of $2-40 min and similar pharmacokinetic properties across species. 19 This is thought to be due to renal clearance and a rapid distribution into tissue, followed by a slower elimination phase proposed to be caused by an equilibrium between post-distribution phase plasma concentrations and tissue concentrations. 20 Inclusion of PS linkages within the backbone of ASOs has shown to increase the blood circulatory half-life, attributed to a non-specific binding with serum proteins such as albumin that may act as an endogenous vector carrying ASOs. 12, 21, 22 Initial biodistribution following systemic administration may be facilitated by binding of PS ASOs to serum proteins, and that lack of serum protein interaction results in kidney filtration. 15, 21, 23, 24 Among the three main plasma proteins studied (albumin, a 2 -macroglobulin, and a 1 -acid glycoprotein), albumin exhibited the strongest binding to PS ASOs using a radiolabeled method, implicating a major role in PS ASOs transport in vivo. 15, 23 PS backbone-mediated binding to plasma proteins has been suggested to be nonspecific low affinity to hydrophilic sites, with no competition displacement shown by a range of albumin binding drugs with known albumin binding sites. 23 Piao et al. 24 showed by fluorescence correlation spectroscopy (FCS) analysis and a gel shift assay the importance of a PS backbone for binding of ASOs to albumin. However, despite the reported binding between PS-modified ASOs and albumin, PS-modified ASOs still exhibit a short circulatory half-life of $2-40 min. 4 Marketed non-oligonucleotide drugs such as fatty acid-modified Levemir and Victoza aim to utilize albumin's intrinsic transport properties and long circulatory half-life for long-lasting therapeutics by fatty acid-mediated binding of endogenous albumin. Advancing the gapmer ASO designs by inclusion of a fatty acid moiety, therefore, offers the possibility to develop a more stable gapmer ASO/HSA construct to facilitate an extended circulatory half-life.
In our work both palmitoyl and myristoyl amino-modified gapmer ASOs bind with HSA as shown by an electrophoretic method. Furthermore, the binding affinity of the gapmer ASOs toward HSA was strongly dependent on number and position of the modifications, and the binding toward HSA increased when replacing PO linkages with PS linkages in the backbone of the gapmer ASOs. We investigated the albumin binding of gapmer ASOs with one or two palmitoyl or myristic acid modifications at varying positions in the gapmer ASOs. Inclusion of two fatty acid modifications such as 2Â palmitoyl or 2Â myristic acids, either two in one wing or one in each of the two wings, exhibited a stronger binding to albumin than a single modification on the same ASOs. Therefore, the modification numbers play a crucial role in binding affinity rather than modification positions. We show by Nanoparticle Tracking Analysis (NTA) a high particle concentration of 7.5 Â 10 9 particles/mL for palmitoylated gapmer ASOs that decreased to 2.5 Â 10 8 particles/mL when incubated with HSA ( Figure S2 ) that suggests interaction and gapmer solubilization. A low 1.9 Â 10 8 particles/mL was observed for gapmer ASOs without fatty acid or backbone modification, similar to 2.4 Â 10 8 particles/ mL of the HSA alone group. To investigate the likelihood of palmitoyl-mediated gapmer ASOs/albumin endogenous assembly for pharmacokinetic modulation, a co-localization gel shift assay was performed following gapmer ASO incubation with mouse serum ( Figure S3) . A distinct gapmer band that co-localized with the predominant serum protein, most likely albumin, was found for the 2Â palmitoyl gapmer ASOs (both 1Â 3 0 -, 1Â 5 0 -palmitoyl and 2Â 3 0 -palmitoyl) in contrast with no restricted migration or co-localization observed for the non-modified gapmer ASO.
In vivo experiments in mice were performed to investigate correlation between serum albumin binding and pharmacokinetics. We showed an increased circulatory half-life of the gapmer ASOs modified with 2Â palmitoyl at the 3 0 end (t 1/2 23 min and t 1/2 49 min for 0Â and 2Â 3 0 -palmitoylated PO gapmer ASOs, respectively). Inclusion of PS linkages further increased the circulatory half-life (t 1/2 28 min and t 1/2 66 min for 0Â and 2Â 3 0 -palmitoylated gapmer ASOs with PS linkages, respectively), suggesting that the effects are additive, which may be attributed to an increased binding to serum albumin, as was observed for the in vitro binding experiments. Rapid binding (<1 min) was found between the 2Â 3 0 -palmitoyl gapmer ASO and recombinant human serum albumin (rHSA) in a gel shift assay (Figure S4) , which supports an instant endogenous assembly process needed to facilitate pharmacokinetic modulation.
Previous studies have shown that gapmer ASOs rapidly transfer from blood into tissues 14 and distribute with highest concentrations in the liver, kidney, bone marrow, adipose tissue, and lymph nodes. 14, 25 We showed that the non-functionalized gapmer ASOs accumulate primarily within the kidney, with trace amounts detected in the liver, lung, and heart in agreement with previous findings for naked ASOs. 26 Inclusion of PS linkages, however, reduced kidney accumulation 2-fold, with a wider biodistribution. The high level of the nonpalmitoyl gapmer ASOs (PO) detected in the kidney at 24 hr, even after rapid clearance from the blood, could be caused by cellular uptake of the gapmer ASOs facilitated by renal excretion events. Addition of 2Â 3 0 -palmitoyls resulted in an increased signal from the liver and a broader biodistribution that resembles that of native albumin demonstrated previously. 16 Chemically modified small interfering RNA (siRNA) has been previously reported to improve systemic stability and biodistribution. 27, 28 Incorporation of LNA and cholesteryl improved siRNA blood circulatory half-life (from <5 min to >30 min) and stability (from 1 min to at least 30 min) compared with unmodified siRNA. 28 We have previously shown that cholesteryl modifications on siRNA extends the plasma half-life and biodistribution more significantly than LNA modification. Correlation was found between albumin binding and modification number, with two cholesteryl modifications showing a plasma half-life of 71 min and 45 min for one cholesteryl modification preformulated with albumin. 29 The gapmer ASO designs described in this work were focused on optimal binding rather than gene silencing activity design considerations. RNase H activity was demonstrated using an in vitro RNase H assay. Escherichia coli RNase H is widely used to compare the effect of nucleotide modifications on RNase H activity 30, 31 and is very structurally similar to the mammalian one, in which the only difference is that the mammalian one contains an N-terminal hybrid binding domain to be more processive. 32 The type of modification was shown to influence the level of target mRNA cleavage (Figure S5) . The inclusion of two palmitoyls at the 3 0 end lowered the activity compared with inclusion of a single palmitoyl at both the 3 0 and 5 0 ends, which suggests a necessity to screen and select designs with combined binding and activity functionality for optimal therapeutic effects for each particular mRNA target. The strong albumin binding observed for the 3 0 -and 5 0 -palmitoyl gapmers identifies potential candidate designs.
In this work, wild-type mice (C57BL/6) were used for ASO pharmacokinetics studies, and HSA was used for investigation of ASO binding. Albumin from different species share a high sequence homology above 70%; 33 however, we cannot discount possible interspecies binding differences that may influence interpretation of in vitro binding and in vivo performance correlation. The availability of a double-transgenic humanized HSA and human neonatal Fc receptor mouse model that better mimics the human physiological conditions could be used for future pharmacokinetics studies. 9 This work introduces a technology platform for a design-based fatty acid modification approach to potentiate endogenous albumin binding for tunable pharmacokinetics of gapmer ASOs. Further development and optimization may offer an attractive alternative to preformulated molecular medicine drug delivery systems.
MATERIALS AND METHODS

ASOs
The gapmer ASOs (ASO 1-12) were prepared by automated oligonucleotide synthesis using commercial DNA and LNA phosphoramidites and palmitoyl-and myristoyl-amino-LNA phosphoramidites using standard methods for oligonucleotide synthesis, workup, purification, and isolation with minor modifications as published for oligonucleotides containing palmitoyl-amino-LNA nucleotide monomers. 34 0 . P and M denote palmitoyl-amino-LNA and myristoyl-amino-LNA thymine monomers, respectively; P* and M* denote palmitoyl-amino-LNA and myristoyl-amino-LNA 5-methyl-cytosine monomers, respectively; A, C, G, and T denote LNA monomers, and a, c, g, and t denote DNA monomers. Underlined sequences are with PS linkages. Gapmer ASOs were dissolved in Nuclease-Free water (Ambion) to 200 mM, and concentrations were determined using an Implen NanoDrop (Thermo Scientific). Oligonucleotides were stored at À20 C.
Self-Assembly of Gapmer ASOs with HSA rHSA (Sigma) was used in this experiment. Binding toward rHSA was carried out by titrating the amount of HSA (0.63-40 mM) to a constant amount of gapmer ASOs (1 mM) in a fixed volume (20 mL). Samples were left to incubate at room temperature for 4 hr before analysis by 8% native gel electrophoresis.
Electrophoretic Mobility Shift Assay
Gel experiments were carried out using the XCell SureLock Mine-Cell Electrophoresis System, using 8% polyacrylamide (National Diagnostics) gels 1Â TBE (Tris-borate-ethylenediaminetetraacetic acid [EDTA]) buffer (from 10Â stock; GIBCO, Life Technologies). Samples were loaded using Novex TBE Running Buffer (5Â) (Invitrogen). Gels were run in 1Â TBE buffer. Staining for gapmer ASOs was performed using SYBR-Gold nucleic acid stain (Invitrogen) following standard protocol.
In Vivo Blood Circulatory Half-Life and Biodistribution of Fatty-Acid-Modified Gapmer ASOs
Seven-to eight-week-old female C57BL/6 mice were maintained for 2 weeks prior to the experiments. To each mouse a dose of 3.5 mg/kg in a total volume of 200 mL of Cy5.5-labeled gapmer ASOs with either 0Â or 2Â 3 0 -palmitoylated modifications, and either PO or PS backbone linkages were administered (n = 5 per gapmer ASO design) by tail-vein injection in a 200 mL volume PBS solution. After injection, blood samples of 10 mL were taken into capillary tubes (Hirschmann Laborgeräte) after 1 min from the tongue, by sublingual vein puncture, and after 30 min, 2 hr, and 4 hr by tail-nicking. At
